CLOs on the Move

G and W Laboratories

www.gwlabs.com

 
Carl Greenblatt founded G&W Laboratories, Inc. in 1919 upon his return from military service as a pharmacist with US forces in World War I. While establishing a reputation as an innovative specialist in suppository dosage forms, Carl guided G&W Laboratories with an uncompromising commitment to product integrity and customer service. In 1945, Carl’s son, Burton, also a registered pharmacist, returned from military service in World War II and joined the small but growing company. During the post-war years, G&W expanded its product line beyond suppositories, into creams, ointments, gels and liquids. G&W moved to a larger state-of-the-art laboratory and production ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.gwlabs.com
  • 111 Coolidge St
    South Plainfield, NJ USA '07080
  • Phone: 908.753.2000

Executives

Name Title Contact Details

Similar Companies

Senior Care Therapy

SCT helps New Jersey nursing homes improve care and reduce expenses by helping to better meet the phsycological needs of residents - at no cost to you

Cardiology Associates

Cardiology Associates of Alabama offers vascular care and heart treatments including structural heart, interventional procedures, pediatric cardiology, heart rhythm disorders, and congestive heart failure.

Pharmaceutical Search Professionals Inc

Pharmaceutical Search Professionals Inc is a North Wales, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Tanabe Research Laboratories U.S.A.

Tanabe Research Laboratories U.S.A., Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.